Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma

N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation

(2011) R. W. J. Groen et al.   HAEMATOLOGICA

Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma

(2011) Georgia M. Beasley et al.   JOURNAL OF CLINICAL ONCOLOGY

The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance

(2010) F. M. Ross et al.   HAEMATOLOGICA

Clinical and pharmacological phase I evaluation of ExherinTM (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours

(2009) A. Perotti et al.   ANNALS OF ONCOLOGY

A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma

(2009) Georgia M. Beasley et al.   CANCER

Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss

(2009) Peter Diamond et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

(2009) E Kastritis et al.   LEUKEMIA